Eli Lilly Combination Antibody Therapy Receives FDA Emergency Use Authorization

[Asia Economy Reporter Hyun-ui Cho] The mixed treatment of Eli Lilly's COVID-19 antibody therapies 'Bamlanivimab' and 'Etesevimab' has received emergency use authorization from the U.S. Food and Drug Administration (FDA).

On the 9th (local time), according to major foreign media, Eli Lilly announced this in a statement. The FDA had previously approved Bamlanivimab as a monotherapy in November last year.

This approval follows subsequent clinical trial results showing that the combined treatment of Bamlanivimab and Etesevimab reduces the risk of hospitalization and death in COVID-19 patients by 70%.

The FDA authorized its use for individuals aged 12 and older who are at risk of developing mild to severe symptoms. However, it did not approve use for severe patients who are hospitalized or require mechanical ventilation.

Eli Lilly's mixed treatment is immediately available for use in medical settings. Eli Lilly stated, "We have already produced 100,000 doses to be used as soon as approval is granted," and added, "Following this approval, we plan to supply an additional 150,000 doses by the first quarter of this year."

Additionally, Eli Lilly announced in the statement that it has partnered with multinational pharmaceutical company Amgen to produce up to 1 million doses of Etesevimab by mid-year.

This content was produced with the assistance of AI translation services.